The effect of using Cannabidiol on the severity of spasticity in MS patients with gait disorders
Phase 3
- Conditions
- Spasticity in multiple sclerosis patients with gait problem.Multiple sclerosis
- Registration Number
- IRCT20220815055709N1
- Lead Sponsor
- Khosro Medisa Teb Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Diagnosis of MS based on McDonald's 2017 criteria by a neurologist
Expanded Disability Status Scale lower than (EDSS<7)
Patients with gait disorder
Age above 18 years
Exclusion Criteria
History of any liver dysfunction
Known sensitivity to any component of the drug
Taking drugs with liver metabolism such as Warfarin, Clobazam, and Sodium valproate
Pregnancy or breastfeeding
Use of marijuana or cannabis-derived compounds in the last 6 months
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The severity of spasticity in Multiple sclerosis patients with gait problem following the use of Cannabidiol. Timepoint: The severity of the patient's spasticity before starting the drug and after 3 and 6 weeks from the start. Method of measurement: Severity of spasticity will be measured based on Numeric rating scale (0-10).
- Secondary Outcome Measures
Name Time Method